- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
- 10-K Annual report
- PDF 10-K
- 10.15 2005 Omnibus Incentive Plan, As Amended on December 28, 2007
- 10.21 Separation Agreement Dated July 31, 2007 by and Between NPS Pharmaceuticals, Inc. and Gregory M. Torre
- 10.30 Asset Purchase Agreement, Dated October 9, 2007
- 10.31 Separation Agreement Dated December 7, 2007 by and Between NPS Pharmaceuticals, Inc. and Val R. Antczak
- 10.32 Separation Agreement Dated November 19, 2007 by and Between NPS Pharmaceuticals, Inc. and Gerard J. Michel
- 10.33 Commercial Manufacturing Agreement, Dated October 18, 2002
- 10.33 Amending Agreement, Dated March 15, 2004
- 10.33 Amendment Number One to Amending Agreement
- 12.1 Ratio of Earnings
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- 10.15 2005 Omnibus Incentive Plan, As Amended on December 28, 2007
- 10.21 Separation Agreement Dated July 31, 2007 by and Between NPS Pharmaceuticals, Inc. and Gregory M. Torre
- 10.30 Asset Purchase Agreement, Dated October 9, 2007
- 10.31 Separation Agreement Dated December 7, 2007 by and Between NPS Pharmaceuticals, Inc. and Val R. Antczak
- 10.32 Separation Agreement Dated November 19, 2007 by and Between NPS Pharmaceuticals, Inc. and Gerard J. Michel
- 10.33 Commercial Manufacturing Agreement, Dated October 18, 2002
- 10.33 Amending Agreement, Dated March 15, 2004
- 10.33 Amendment Number One to Amending Agreement
- 12.1 Ratio of Earnings
- 21.1 Subsidiaries
- 23.1 Consent
- 31.1 CEO 302 Certificate
- 31.2 CFO 302 Certificate
- 32 906 Certificate
- 10.2 1998 Stock Option Plan Thru December 2007
- 10.2 1998 Stock Option Plan Thru December 2007
Exhibit 32.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
AND CHIEF FINANCIAL OFFICER
Pursuant to
18 U.S.C. Section 1350,
as Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
Solely for the purposes of complying with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we the undersigned Chief Executive Officer and Chief Financial Officer of NPS Pharmaceuticals, Inc. certify that the Annual Report of NPS Pharmaceuticals, Inc. on Form 10-K for the fiscal year ended December 31, 2007 fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that information contained in such Annual Report on Form 10-K fairly presents in all material respects, the financial condition and results of operations of NPS Pharmaceuticals, Inc.
Date: March 14, 2008 | /s/ N. ANTHONY COLES N. Anthony Coles President and Chief Executive Officer |
Date: March 14, 2008 | /s/ LUKE M. BESHAR Luke M. Beshar Senior Vice President and Chief Financial Officer |
The foregoing certification is being furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code) and is not being filed as part of the Form 10-K or as a separate disclosure document.
A signed original of this written statement required by Section 906 has been provided to NPS Pharmaceuticals, Inc. and will be retained by NPS Pharmaceuticals, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.